An indirect treatment comparison shows that dupilumab and tezepelumab yield broadly similar clinical benefits in patients ...

Nasal polyp development, treatment, and recurrence were topics up for discussion in this year’s most popular nasal polyps–related content. Nasal polyp development, treatment, and recurrence, as well ...

Researchers discuss contributors to nasal polyp development in children, as well as the risk of co-occuring conditions and current methods of treatment. Although rarely reported in childhood, nasal ...

SAN DIEGO -- Tezepelumab (Tezspire) reduced nasal polyps and symptoms in severe chronic rhinosinusitis while also decreasing need for further treatments, the WAYPOINT trial showed. The monoclonal ...

For severe chronic rhinosinusitis with nasal polyps, the novel monoclonal antibody stapokibart reduced symptoms and polyp size atop treatment with a daily intranasal corticosteroid. The polyp size ...

Please provide your email address to receive an email when new articles are posted on . Dupilumab is the first treatment in the U.S. for CRSwNP for adolescents. The approval is supported by data from ...

Treating nasal polyps isn’t a one-and-done procedure. The complications from these growths, which develop in the lining of ...

GSK has secured European Commission approval for Exdensur (depemokimab) to treat severe asthma with type 2 inflammation and ...

On Monday, GSK plc (NYSE:GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the efficacy and safety of depemokimab versus placebo in adults with chronic ...

The European approval for GSK's depemokimab joins recently announced data on vaccine efficacy and progress on 4-month viral treatments.